Journal of cellular immunology最新文献_第8页

Megalin-Mediated Trafficking of Mitochondrial Intracrines: Relevance to Signaling and Metabolism. 巨噬细胞蛋白介导的线粒体内分泌:与信号传导和代谢相关。

Journal of cellular immunology Pub Date : 2021-11-23

David Sheikh-Hamad, Michael Holliday, Qingtian Li

引用次数: 0

Neurological Manifestations Associated with SARS-CoV-2 Invasion of the Autonomous Nervous System 与SARS-CoV-2入侵自主神经系统相关的神经学表现

Journal of cellular immunology Pub Date : 2021-10-10 DOI: 10.33696/immunology.3.107

Erwan Poivet, M. Daniel, F. Bozza, T. Sharshar, Pierre-Marie, Lledó

引用次数: 0

Commentary on “A Vaccine for Photodynamic Immunogenic Cell Death: Tumor Cell Caged b y Cellular Disulfide–Thiol Exchange for Immunotherapy” 《一种光动力免疫原性细胞死亡疫苗:细胞二硫化物-硫醇交换法免疫治疗肿瘤细胞》评论

Journal of cellular immunology Pub Date : 2021-10-10 DOI: 10.33696/immunology.3.109

J. Zang, Haiqing Dong

引用次数: 0

Expression of Pu.1, C/Ebp? and Bach1 Transcription Factors in Immune Cells in Patients with Cancer Pu.1，C/Ebp的表达？癌症患者免疫细胞中Bach1转录因子的表达

Journal of cellular immunology Pub Date : 2021-10-10 DOI: 10.33696/immunology.3.106

G. Zakiryanova, E. Kustova, N. Urazalieva, Emile T. Baimukhametov, V. A. Makarov, G. Shurin, Narymzhan N. Nakisbekov, M. Shurin

引用次数: 0

Novel Combination Treatments for AML AML的新型联合治疗

Journal of cellular immunology Pub Date : 2021-10-10 DOI: 10.33696/immunology.3.105

引用次数: 2

Establishment of an Indirect Enzyme-linked Immunosorbent Assay for Detection of the NS4 Protein of Bluetongue Virus 间接酶联免疫吸附法检测蓝舌病毒NS4蛋白的建立

Journal of cellular immunology Pub Date : 2021-09-12 DOI: 10.33696/immunology.4.148

Ji Ma, Xianping Ma, Rang Wang, Fang Li, T. Hu, Huashan Yi

引用次数: 0

Efficacy of Therapeutic Plasma Exchange Alone or in Combination with Ruxolitinib for the Treatment of Penn Class 3 and 4 Cytokine Release Syndrome Complicating COVID-19 治疗性血浆置换或联合鲁索利替尼治疗Penn 3、4类细胞因子释放综合征合并COVID-19的疗效观察

Journal of cellular immunology Pub Date : 2021-09-01 DOI: 10.33696/immunology.3.100

W. L. Gluck, Wesley M. Smith, S. P. Callahan, Robert A. Brevetta, A. Stenbit, J. Martin, Anna V. Blenda, S. Arce, W. Edenfield

{"title":"Efficacy of Therapeutic Plasma Exchange Alone or in Combination with Ruxolitinib for the Treatment of Penn Class 3 and 4 Cytokine Release Syndrome Complicating COVID-19","authors":"W. L. Gluck, Wesley M. Smith, S. P. Callahan, Robert A. Brevetta, A. Stenbit, J. Martin, Anna V. Blenda, S. Arce, W. Edenfield","doi":"10.33696/immunology.3.100","DOIUrl":"https://doi.org/10.33696/immunology.3.100","url":null,"abstract":"Observations early in the viral pandemic of 2020 noted the resemblance between severe coronavirus disease 2019 (COVID-19) infection and the hypercytokinemic state of secondary hemophagocytic lymphohistiocytosis (sHLH) [1]. Conti and colleagues [2] have outlined the binding of COVID-19 to the Toll-like receptor with subsequent cytokine driven fever and pneumonitis, while in Kenderian’s [3] murine model of CRS, ruxolitinib abrogated the development of cytokine excess. Cao [4] reported faster clinical recovery with JAK inhibition and Capochiani’s RESPIRE trial reported an 89% overall response rate (ORR) with ruxolitinib therapy [5]. Discordant findings regarding JAK inhibition have been reported on the superiority of baricitinib plus remdesivir over remdesivir alone in shortening recovery times in hospitalized patients [6] while the randomized RUXCOVID trial failed to impact severe complications of the disease by adding ruxolitinib to standard of care [7]. Other groups [8,9] have reported inflammatory cytokine profiles along with evidence that elevated IL-6 and TNFα are strong predictors of disease severity and survival. While cytokine excess could be an epiphenomenal surrogate for another process, therapeutic strategies have evolved around addressing the excessive cytokine levels complicating a significant fraction of COVID-19 patients.","PeriodicalId":73644,"journal":{"name":"Journal of cellular immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46372997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Body Mass Index and Covi d-19: Likely Causes for Obesity and Undernutrition Correlation with Disease Severity 体重指数和covid -19:肥胖和营养不良与疾病严重程度相关的可能原因

Journal of cellular immunology Pub Date : 2021-09-01 DOI: 10.33696/immunology.3.104

Nicolas Vitale

引用次数: 0

Environmental Enrichment and Its Benefits for Migraine: Dendritic Cell Extracellular Vesicles as an Effective Mimetic 环境富集及其对偏头痛的益处:树突状细胞胞外囊泡是一种有效的模拟物

Journal of cellular immunology Pub Date : 2021-07-16 DOI: 10.33696/immunology.3.102

K. Pusic, L. Won, R. P. Kraig, A. Pusic

引用次数: 1

Increased Binding Affinity of Furin to D614G Mutant S-glycoprotein May Augment Infectivity of the Predominating SARS-CoV-2 Variant Furin与D614G突变S-糖蛋白结合亲和力的增加可能增强主要严重急性呼吸系统综合征冠状病毒2型变异株的感染性

Journal of cellular immunology Pub Date : 2021-06-30 DOI: 10.33696/immunology.3.095

Sardar Sindhu, R. Ahmad, F. Al-Mulla

{"title":"Increased Binding Affinity of Furin to D614G Mutant S-glycoprotein May Augment Infectivity of the Predominating SARS-CoV-2 Variant","authors":"Sardar Sindhu, R. Ahmad, F. Al-Mulla","doi":"10.33696/immunology.3.095","DOIUrl":"https://doi.org/10.33696/immunology.3.095","url":null,"abstract":"The coronavirus disease (COVID)-19 pandemic has profoundly devastated human health and wellbeing all over the world, along with colossal setback to global economy in terms of soaring new infections, hospitalizations, ICU admissions, work losses, closures of businesses and institutions, bankruptcies, and precautionary measures involving social distancing, hygiene, and travel restrictions across the globe. COVID-19 was declared by the World Health Organization (WHO) as a public health emergency of international concern in January 2020, and then as a pandemic in March 2020. There are over 154.64 million confirmed coronavirus infections and more than 3.23 million deaths reported to the WHO globally until date (as of 11:21 a.m. CEST, 6 May, 2021) [1]. The disease is caused by a zoonotic positive-sense single-stranded ssRNA virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is known to have four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N), with close genetic similarity to bat coronaviruses. The global science initiative source called “Global Initiative on Sharing Avian Influenza Data” (GISAID) has reported seven SARS-CoV-2 clades as G, GH, GR, L, O, S, and V [2].","PeriodicalId":73644,"journal":{"name":"Journal of cellular immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47435250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1